The Alliance for Regenerative Medicine (ARM), a global advocacy organization active since 2009, has recently published the ARM Quarterly Data Report on the state of regenerative medicine industry.
The report includes analysis of trends and metrics provided by 580 therapeutic companies worldwide. More than 300 of these companies are located in North America.
“This sector has come off a strong year in 2014 and 2015 is off to an even stronger start. As 2015 continues to unfold, we anticipate more high-value deals, and increased investor and public interest in what advanced therapies can offer.” Patricia Reilly and Nancy Dvorin from Informa Business Intelligence, Pharma and Healthcare, ARM’S data partner, wrote in the report.
Higher investments in advanced therapies are in fact among the major trends of the first quarter of 2015. Currently, 486 clinical trials (phase I, II or III) are underway. More than 1/3 of current clinical trials are in oncology, and more than 1/10 are in the cardiovascular area.
Additional ARM reports, released at the end of each quarter of the year, will include updates to the current information. To view and download the Q1 Report click here.